RINE BIOMARKER SCREENING FOR PROSTATE CANCER
Not Applicable
- Conditions
- Health Condition 1: N429- Disorder of prostate, unspecified
- Registration Number
- CTRI/2021/09/036323
- Lead Sponsor
- Medicametrix
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Cohort randomized prospective study, signed informed consent, Male between age 45 AND 85 suspected case of prostate cancer (PCa) before biospy, Total PSA & Free PSA, 4K Score/PHI, Prostate volume, Testoterone, Routine urine analysis, Biochemical test,transrectal ultrasound (TRUS)-guided biopsies or DRE, MR Scan,microscopic anatomy, Gleason Score and estimates the overall â??Cancer Aggressivenessâ?? Score Sandwich Elisa.
Exclusion Criteria
Patients come for second and third opinions, Unable to perform a Rectal Examination or any reason, Certain Lower Urinary Tract Congenital Abnormalities inability to understand or give informed consent, Patients with history of HIV, HBV, TB.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Identify whether selected panels of urinary biomarkers before prostate biopsy that will provide promising novel tool to guide clinical decision making for prostate cancer (PCa) treatment and management.Timepoint: One Year
- Secondary Outcome Measures
Name Time Method Validation of selected urinary biomarkers for pilot studyTimepoint: One Year